Top Artificial Intelligence-Based Healthcare Mobile Apps and Their Use Cases
Top Artificial Intelligence-Based Healthcare Mobile Apps and Thei...
Assessing the Growing Role & the Demand of Apps in Managing...
Top 12 Most Expensive Drugs in the US Healthcare Market
Analyzing the Most Promising Drugs That Will Lose Patent in the U...
Emerging Market for Organ on a Chip

Search by Categories

Home / Blog / Endocrinology and metabolic disorders / 6

Endocrinology and Metabolic Disorders

Medtronic Launches Infusion Set for Insulin Pum...

Medtronic Launches World's First and Only Infusion Set for Insulin Pumps that Doubles Wear Time up to 7 days in the US  On November 15, 2022, Medtronic plc, a global leader in healthcare technology...

Nov 17, 2022

MedTech News for Medtronic, Penumbra, and Genesis
Innovation and Advances in Type 2 Diabetes Treatment and Management
Insights Into the Key Advancements Transforming the Type 2 Diabetes Treatment and Management

Diabetes is a chronic metabolic disorder that is influenced by a wide variety of factors and is characterized by high or low blood glucose (or blood sugar) levels in the body. Diabetes is a major risk factor for blindness, kidney failure, heart attacks, stroke, and lower limb amputation. Also, it can significantly ...

Find More
MedTech News for Enspectra, Mentice, and EndoStim
FDA Approval to DePuy TELIGEN System; FDA Breakthrough Device Designation for the EndoStim System; GE and Accuray Announces Collaboration; Mentice and Acandis Announces a Three-Year Agreement; Indigo Diabetes Enrolled First Participant in the Shine Clinical Trial; FDA IDE Approval to MedAlliance’s SELUTION SLR

DePuy Synthes Received FDA Approval for TELIGEN™ System  On October 20, 2022, DePuy Synthes, The Orthopaedics Company of Johnson & Johnson, provides one of the most comprehensive orthopedics portfolios in the world that helps heal and restore movement for the millions of patients, announced that ...

Find More
MedTech Updates for Neuspera, Abbott, and ZEISS,
Neuspera Medical’s Nuvella System; Abbott Presented the Data for FreeStyle Libre 2 System; ZEISS Receives FDA 510(k) Clearance for MTLawton; FDA 510(k) Clearance for the GHOST 3D-Printed Titanium Spacer System; Thermo Fisher Scientific Launched CE-IVD Marked TaqPath Enteric Bacterial Select Panel; BIOCORP and Merck Announced New Partnership

Neuspera Medical Announces First Successful Implant of the Nuvella™ System in the Second Phase of Its Sans-Uui Ide Clinical Trial On October 10, 2022, Neuspera Medical, a medical device company involved in the development of implantable devices for patients suffering from chronic illnesses, announced that...

Find More

More Views & Analysis

MedTech News for Olympus and Fujifilm
Olympus’s THUNDERBEAT Open Fine Jaw Type X Surgical Energy Device; Merit Medical’s TEMNO Elite; Thermo Fisher Scientific’s Oncomine Dx Target Test; Fujifilm Latest Generation Endoscopic Ultrasound; Indigo Diabetes’s Shine Clinical Trial; Cala Health Published Data for its TAPS Therapy

Olympus Launched THUNDERBEAT Open Fine Jaw Type X Surgical Energy Device On September 28, 2022, Olympus Corporation (Olympus), a global MedTech company, announced the release of the THUNDERBEAT™ Open Fine Jaw Type X surgical energy devices for open surgery. The device THUNDERBEAT Open Fine Jaw Type X surg...

Find More
Pharma News and Updates for Akero Chiesi Pfizer
AstraZeneca’s Danicopan Trial; CHMP Recommends Sanofi/AstraZeneca’s nirsevimab; Akero’s NASH Drug Trial; FDA Grants Orphan Drug Status to SY-5609; BMS’s Opdivo Trial Results; Pfizer to File for FDA Approval for Meningitis Vaccine; EMA Orphan Drug Designation to CAN-2409; FDA Starts Priority Review of Chiesi ‘s velmanase alfa

AstraZeneca’s Danicopan Shows Positive Results in Phase III Trial Danicopan, an oral Factor D inhibitor developed by AstraZeneca, was expected to fail a phase II trial in rare kidney disease in 2020, but a new readout could revive the drug. Danicopan (ALXN2040) has demonstrated efficacy as an adjunct treatment f...

Find More
Latest MedTech News for Olympus and Aerin
Aerin Medical’s RhinAer Stylus; CE Mark for Haemonetics’s VASCADE Vascular Closure Device; J&J Vision Launches ACUVUE OASYS MAX 1-Day; Olympus Launches VISERA ELITE III Surgical Visualization Platform; GlucoRx’s Non-Invasive Glucose Monitoring Platform; Medtronic-BioIntelliSense’s Partnership; Corindus’s CorPath GRX Neurovascular System Trial; GE & Lantheus [18F]flurpiridaz PET Radiotracer Trial; Pulmonx’s AeriSeal System Trial; AtriAN’s Second Study on Cardioneuroablation

Johnson & Johnson Vision Launches New Contact Lens Innovation ACUVUE® OASYS MAX 1-Day for Meeting the Needs of Digitally Intense Lifestyles On September 12, 2022, Johnson & Johnson Vision, a part of Johnson & Johnson and a global leader in the eyecare market, had announced the launch of its newest in...

Find More
Pharma News for Amgen BioNTech and Gilead
Amgen Announced the Result of its CodeBreak-200 Trial; FDA Clears Bristol-Myers Squibb’s Deucravacitinib; BioNTech’s Amplified CAR-T Therapy; TIL Therapy Improves on Yervoy in Melanoma; GSK’s Daprodustat will have to face FDA Advisory Committee; Breakthrough Therapy Status to Pfizer’s Group B Strep Vaccine; EU Approves Gilead’ Tecartus; Gilead’ Trodelvy Results in TROPiCs-02 Trial

Amgen Reveals the Top-line Result of its CodeBreak-200 trial of Lumakras in Lung Cancer The top-line result of Amgen's CodeBreak-200 trial of Lumakras in lung cancer was presented in abstract form at ESMO two weeks ago, showing a 34% improvement in progression-free survival (PFS) compared to chemotherapy. The fu...

Find More
Pharma News for Aktis, Alcon and Takeda
Aktis’s Novel Targeted Alpha Radiopharmaceuticals; Koye Partners with Sonde Health; Novartis to Spin Off Sandoz Business; Alcon to Buy Aerie Pharma; Fast Track Designation to Merck’s MK-2060; FDA Approves Ibrutinib for Chronic GvHD; French Authorities Clears BrainVectis’s Clinical Trial; Takeda’s Dengue Vaccine TAK-003 Gets Approval in Indonesia

Aktis Oncology Raises USD 84 Million To Advance Novel Targeted Alpha Radiopharmaceuticals Aktis Oncology has raised an additional USD 84 million in its Series A round, adding to the USD 72 million raised last year to help bring its radiopharmaceuticals to market. The extension to the first round included Merck's...

Find More
congenital-adrenal-hyperplasia-treatment-landscape
Will The Emerging Pipeline Address The Congenital Adrenal Hyperplasia Treatment Puzzle?

Congenital adrenal hyperplasia (CAH) is a rare inherited autosomal recessive disorder defined by a lack of one of the enzymes required to produce specific hormones. In the United States and Europe, the most prevalent type of CAH, 21 hydroxylase deficiency, affects around 1:10,000 to 1:15,000 people. The estimated C...

Find More

T cell Lymphoma (TCL) is cancer that develops in the T-lymphocytes. T-cell Lymphomas are majorly cla.....

Find More

Dry Age-related Macular Degeneration (Dry AMD), also called atrophic AMD, is the most common form of.....

Find More

With worldwide dissemination and now over 9 million cases and nearly 500,000 deaths recorded, the ef.....

Find More

RNAi is a fundamental gene-silencing pathway in eukaryotic cells, where long pieces of double-strand.....

Find More

Thyroid Eye Disease (TED), also known as Grave’s Ophthalmopathy, is an autoimmune disorder in whic.....

Find More

AAV Vectors are the leading viral vectors for gene delivery to treat a variety of human diseases. Ad.....

Find More